Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003248 | 0.83 | IDO1 (0.40) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL2540816 | 0.79 | L3MBTL1 (0.48) | IDO1MAPTCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL7434026 | 0.78 | CYP3A4 (0.46) | IDO1MEN1KMT2ATHRBTDP1 | |
| Hydrochloric Acid SCHEMBL3659014 | 0.78 | L3MBTL1 (0.52) | IDO1MEN1KMT2AMAPTCYP3A4 | |
| SCHEMBL10428573 | 0.76 | ALDH1A1 (0.49) | IDO1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11661655 | 0.74 | IDO1 (0.52) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL5218360 | 0.73 | PDE4A (0.36) | ALDH1A1HPGD | |
| SCHEMBL12805042 | 0.72 | HRAS (0.42) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL6601395 | 0.72 | HRAS (0.42) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL28493636 | 0.72 | CA2 (0.47) | IDO1MEN1KMT2ATHRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106928095-A | Cyano group ketene tricyclic diterpene analog and its preparation method and application | 华东师范大学 | 2017-07-07 | — | — | CN | claimed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | claimed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| WO-2020192562-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| CN-109678815-A | N- benzyl benzamide derivatives and preparation method thereof and pharmaceutical applications | 中国药科大学 | 2019-04-26 | — | — | CN | disclosed |
| EP-1659881-B1 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | SENOMYX INC (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3431464-A2 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | Senomyx Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| CN-107635963-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2018-01-26 | — | — | CN | disclosed |
| US-9776991-B2 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2017-10-03 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| WO-2002100842-A1 | SULFONYLOXAZOLAMINES AND THEIR USE AS 5-HT6 LIGANDS | MERCK PATENT GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-0923562-B1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-6444616-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| CN-1227548-A | Substituted p-trifluoromethylphenyluracils | BAYER AG (DE) | 1999-09-01 | — | — | CN | disclosed |
| CN-1225083-A | Calcium receptor-active compounds | KIRIN BREWERY (JP) | 1999-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | IDO1 4379/4885MEN1 2625/4885KMT2A 2908/4885 |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | CACNA1B, CACNG6, SCN5A | IDO1 4379/4885MEN1 2625/4885KMT2A 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.